tiprankstipranks
Kura Oncology (KURA)
NASDAQ:KURA
US Market
Want to see KURA full AI Analyst Report?

Kura Oncology (KURA) Stock Forecast & Price Target

844 Followers
See the Price Targets and Ratings of:

KURA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Kura
Oncology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KURA Stock 12 Month Forecast

Average Price Target

$28.13
▲(190.55% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $28.13 with a high forecast of $40.00 and a low forecast of $15.00. The average price target represents a 190.55% change from the last price of $9.68.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","41":"$41","13.25":"$13.25","22.5":"$22.5","31.75":"$31.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,13.25,22.5,31.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.34,10.775384615384615,13.21076923076923,15.646153846153846,18.08153846153846,20.516923076923078,22.95230769230769,25.38769230769231,27.823076923076922,30.258461538461535,32.69384615384615,35.12923076923077,37.56461538461538,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.34,9.861923076923077,11.383846153846154,12.90576923076923,14.427692307692308,15.949615384615385,17.47153846153846,18.99346153846154,20.515384615384615,22.037307692307692,23.55923076923077,25.081153846153846,26.603076923076923,{"y":28.125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.34,8.852307692307692,9.364615384615384,9.876923076923077,10.38923076923077,10.901538461538461,11.413846153846155,11.926153846153847,12.438461538461539,12.95076923076923,13.463076923076922,13.975384615384616,14.487692307692308,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$28.13Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on KURA
Barclays
Barclays
$28
Buy
189.26%
Upside
Reiterated
04/20/26
Barclays Sticks to Their Buy Rating for Kura Oncology (KURA)
H.C. Wainwright Analyst forecast on KURA
H.C. Wainwright
H.C. Wainwright
$37$40
Buy
313.22%
Upside
Reiterated
04/20/26
H.C. Wainwright Reaffirms Their Buy Rating on Kura Oncology (KURA)
Bank of America Securities Analyst forecast on KURA
Bank of America Securities
Bank of America Securities
$30
Buy
209.92%
Upside
Reiterated
04/17/26
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
LifeSci Capital Analyst forecast on KURA
LifeSci Capital
LifeSci Capital
$24$28
Buy
189.26%
Upside
Reiterated
04/16/26
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
Lake Street Analyst forecast on KURA
Unknown Analyst
Lake Street
Not Ranked
Lake Street
$23
Buy
137.60%
Upside
Initiated
04/14/26
Kura Oncology initiated with a Buy at Lake StreetKura Oncology initiated with a Buy at Lake Street
Mizuho Securities Analyst forecast on KURA
Mizuho Securities
Mizuho Securities
$30$25
Buy
158.26%
Upside
Assigned
03/24/26
Analysts Offer Insights on Healthcare Companies: Pharming Group (NASDAQ: PHAR) and Kura Oncology (NASDAQ: KURA)
UBS
$16$15
Buy
54.96%
Upside
Assigned
03/13/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)
Guggenheim Analyst forecast on KURA
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
Hold
Reiterated
03/06/26
Kura Oncology (KURA) Receives a Hold from Guggenheim
Wedbush
$38$36
Buy
271.90%
Upside
Reiterated
03/06/26
Kura Oncology price target lowered to $36 from $38 at WedbushKura Oncology price target lowered to $36 from $38 at Wedbush
TD Cowen Analyst forecast on KURA
TD Cowen
TD Cowen
Buy
Reiterated
03/05/26
Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
Leerink Partners Analyst forecast on KURA
Leerink Partners
Leerink Partners
$25$20
Buy
106.61%
Upside
Reiterated
01/13/26
Kura Oncology (KURA) Receives a Buy from Leerink Partners
Jefferies Analyst forecast on KURA
Jefferies
Jefferies
$28
Buy
189.26%
Upside
Reiterated
12/10/25
Kura Oncology (KURA) Gets a Buy from Jefferies
BTIG
Hold
Reiterated
12/09/25
BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)
Citizens JMP Analyst forecast on KURA
Citizens JMP
Citizens JMP
$24
Buy
147.93%
Upside
Reiterated
09/30/25
Kura Oncology (KURA) Gets a Buy from Citizens JMP
Cantor Fitzgerald Analyst forecast on KURA
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
06/26/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on KURA
Barclays
Barclays
$28
Buy
189.26%
Upside
Reiterated
04/20/26
Barclays Sticks to Their Buy Rating for Kura Oncology (KURA)
H.C. Wainwright Analyst forecast on KURA
H.C. Wainwright
H.C. Wainwright
$37$40
Buy
313.22%
Upside
Reiterated
04/20/26
H.C. Wainwright Reaffirms Their Buy Rating on Kura Oncology (KURA)
Bank of America Securities Analyst forecast on KURA
Bank of America Securities
Bank of America Securities
$30
Buy
209.92%
Upside
Reiterated
04/17/26
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
LifeSci Capital Analyst forecast on KURA
LifeSci Capital
LifeSci Capital
$24$28
Buy
189.26%
Upside
Reiterated
04/16/26
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
Lake Street Analyst forecast on KURA
Unknown Analyst
Lake Street
Not Ranked
Lake Street
$23
Buy
137.60%
Upside
Initiated
04/14/26
Kura Oncology initiated with a Buy at Lake StreetKura Oncology initiated with a Buy at Lake Street
Mizuho Securities Analyst forecast on KURA
Mizuho Securities
Mizuho Securities
$30$25
Buy
158.26%
Upside
Assigned
03/24/26
Analysts Offer Insights on Healthcare Companies: Pharming Group (NASDAQ: PHAR) and Kura Oncology (NASDAQ: KURA)
UBS
$16$15
Buy
54.96%
Upside
Assigned
03/13/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)
Guggenheim Analyst forecast on KURA
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
Hold
Reiterated
03/06/26
Kura Oncology (KURA) Receives a Hold from Guggenheim
Wedbush
$38$36
Buy
271.90%
Upside
Reiterated
03/06/26
Kura Oncology price target lowered to $36 from $38 at WedbushKura Oncology price target lowered to $36 from $38 at Wedbush
TD Cowen Analyst forecast on KURA
TD Cowen
TD Cowen
Buy
Reiterated
03/05/26
Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
Leerink Partners Analyst forecast on KURA
Leerink Partners
Leerink Partners
$25$20
Buy
106.61%
Upside
Reiterated
01/13/26
Kura Oncology (KURA) Receives a Buy from Leerink Partners
Jefferies Analyst forecast on KURA
Jefferies
Jefferies
$28
Buy
189.26%
Upside
Reiterated
12/10/25
Kura Oncology (KURA) Gets a Buy from Jefferies
BTIG
Hold
Reiterated
12/09/25
BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)
Citizens JMP Analyst forecast on KURA
Citizens JMP
Citizens JMP
$24
Buy
147.93%
Upside
Reiterated
09/30/25
Kura Oncology (KURA) Gets a Buy from Citizens JMP
Cantor Fitzgerald Analyst forecast on KURA
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
06/26/25
Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kura Oncology

3 Months
xxx
Success Rate
13/23 ratings generated profit
57%
Average Return
+11.33%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +11.33% per trade.
1 Year
Success Rate
13/23 ratings generated profit
57%
Average Return
+19.94%
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +19.94% per trade.
2 Years
xxx
Success Rate
13/23 ratings generated profit
57%
Average Return
-2.51%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 56.52% of your transactions generating a profit, with an average return of -2.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KURA Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
24
21
14
16
16
Buy
8
6
2
2
1
Hold
3
3
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
30
17
19
18
In the current month, KURA has received 17 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KURA average Analyst price target in the past 3 months is 28.13.
Each month's total comprises the sum of three months' worth of ratings.

KURA Financial Forecast

KURA Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

KURA Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

KURA Stock Forecast FAQ

What is KURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kura Oncology’s 12-month average price target is 28.13.
    What is KURA’s upside potential, based on the analysts’ average price target?
    Kura Oncology has 190.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KURA a Buy, Sell or Hold?
          Kura Oncology has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Kura Oncology’s price target?
            The average price target for Kura Oncology is 28.13. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $15.00. The average price target represents 190.55% Increase from the current price of $9.68.
              What do analysts say about Kura Oncology?
              Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of KURA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.